Bioavailability of Cariban® Capsules: A Modified-Release Fixed-Dose Combination of Doxylamine and Pyridoxine to Relieve Nausea and Vomiting During Pregnancy

被引：0
|
作者：
Paula Saz-Leal
Laura Zamorano-Domínguez
Jesús Frías
Pedro Guerra
Marc Saura-Valls
Ramón Roca-Juanes
Joaquín Nebot-Troyano
Eva García-Aguilar
Tatiana Vilchez
Katia Urso
机构：
[1] ITF Research Pharma S.L.U.,Medical Department
[2] ITF Research Pharma S.L.U.,R&D Department
[3] IdiPAZ,Clinical Pharmacology Department, La Paz University Hospital, School of Medicine
[4] Autonomous University of Madrid,undefined
[5] Inibsa Ginecologia S.A,undefined
来源：
Drugs in R&D | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：185 / 195
页数：10
相关论文
共 42 条
  • [21] MODELING AND SIMULATIONS TO SUPPORT DOSING REGIMEN OF A FIXED-DOSE COMBINATION PRODUCT OF IMMEDIATE-RELEASE PHENTERMINE AND MODIFIED-RELEASE TOPIRAMATE (VI-0521) IN PATIENTS WITH RENAL IMPAIRMENT
    Trinh, M. M.
    Mouksassi, M. S.
    Chang, C.
    Marier, J. F.
    Peterson, C.
    Yee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S79 - S79
  • [22] MODELING AND SIMULATIONS TO DETERMINE THE EFFECT OF A FIXED-DOSE COMBINATION PRODUCT OF IMMEDIATE-RELEASE PHENTERMINE AND MODIFIED-RELEASE TOPIRAMATE (VI-0521) ON HEART RATE IN OBESE PATIENTS
    PeyreLl, T.
    Gosselin, N. H.
    Mouksassi, M. S.
    Marier, J. F.
    Yee, S.
    Day, W. W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S78 - S79
  • [23] MODELING AND SIMULATIONS TO SUPPORT DOSING REGIMEN OF A FIXED-DOSE COMBINATION PRODUCT OF IMMEDIATE-RELEASE PHENTERMINE AND MODIFIED-RELEASE TOPIRAMATE (VI-0521) IN PATIENTS WITH HEPATIC IMPAIRMENT
    Mouksassi, M. S.
    Trinh, M. M.
    Chang, C.
    Marier, J. F.
    Peterson, C.
    Yee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S79 - S79
  • [24] Comparison of Pharmacokinetics and Bioavailability of Fixed-Dose Combination Tablet and Monotherapy Combination of Allisartan Isoproxil and Indapamide Sustained-Release in Healthy Chinese Volunteers
    Fan, Ni
    Zhou, Gongmin
    Cheng, Wenming
    Jiao, Yang
    Zhang, Ruijie
    Yan, Chen
    Tong, Xiangming
    Yi, Wu
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (02): : 190 - 196
  • [25] Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.
    Aapro, Matti S.
    Karthaus, Meinolf
    Schwartzberg, Lee Steven
    Rossi, Giorgia
    Rizzi, Giada
    Borroni, Maria Elisa
    Palmas, Marco
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Improved control of nausea and vomiting (CINV) with a fixed-dose combination of netupitant and palonosetron (NEPA) following highly emetogenic chemotherapy (HEC): Results from a pivotal study
    Gralla, R.
    Rossi, G.
    Rizzi, G.
    Palmas, M.
    Alyasova, A.
    Drobner, I.
    Hesketh, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S267 - S267
  • [27] Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
    Nilsson, Jonas
    Piovesana, Vittoria
    Turini, Marco
    Lezzi, Claudio
    Eriksson, Jennifer
    Aapro, Matti
    SUPPORTIVE CARE IN CANCER, 2022, 30 (11) : 9307 - 9315
  • [28] Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
    Jonas Nilsson
    Vittoria Piovesana
    Marco Turini
    Claudio Lezzi
    Jennifer Eriksson
    Matti Aapro
    Supportive Care in Cancer, 2022, 30 : 9307 - 9315
  • [29] PHARMACOECONOMIC ANALYSIS OF USING SOLIFENACIN AND MODIFIED-RELEASE TAMSULOSIN FIXED DOSE COMBINATION FOR TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
    Avxentyev, N.
    Frolov, M.
    VALUE IN HEALTH, 2017, 20 (09) : A488 - A489
  • [30] Efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
    Aapro, M.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Grunberg, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S266 - S266
12345